William J. Jusko PhD

William J. Jusko
PhD

SUNY Distinguished Professor

Department of Pharmaceutical Sciences

School of Pharmacy

Specialty/Research Focus

Pharmacodynamic; Pharmacogenomics; Pharmacokinetic; PK/PD

Contact Information

404 Pharmacy Building
Buffalo, NY 14214-8033
Phone: (716) 645-2855
Fax: 7168296569
wjjusko@buffalo.edu

View map

View faculty website

Overview Research Publications Activities Latest News

Professional Summary:

Research interests are in theoretical, basic, and clinical aspects of the pharmacokinetics and pharmacodynamics of various immunosuppressive agents including corticosteroids, as well as drugs used to treat diabetes, inflammation, and cancer. With Drs. Richard Almon and Debra DuBois, Dr. Jusko delves into the pharmacogenomics of diverse effects of corticosteroids and has evolved advanced mathematical models of receptor/gene-mediated responses. They have characterized the effects of corticosteroids on hepatic and muscle enzymes and tissue responses and have evolved advanced PK/PD models for cascade-type processes. Dr. Jusko has developed mechanism-based pharmacokinetic, pharmacodynamic, and disease progression models and computational methods describing the action of various drugs and utilizes mathematical models of drug action to determine optimal dosage regimens diverse drugs.

Education and Training:

PhD, Pharmaceutical Sciences, State University of New York at Buffalo (1970)
BPharm, State University of New York at Buffalo (1965)
Secondary Education High School Diploma, Salamanca High School (1960)

Employment:

SUNY Distinguished Professor, Pharmaceutical Sciences, University at Buffalo (2008-present)
Director, Center of Excellence in Pharmacokinetics and Pharmacodynamics, Pharmaceutical Sciences, University at Buffalo (2005-present)
Chair, Department of Pharmaceutical Sciences, University at Buffalo (2001–2016)
UB Distinguished Professor, Department of Pharmaceutical Sciences, University at Buffalo (2007–2008)
Professor, Pharmaceutical Sciences, University at Buffalo (1977–2007)
Vice-Chairman, Department of Pharmacy, Department of Pharmacy, University at Buffalo (1984–1986)
Director, Doctor of Pharmacy Program, Pharmacy, University at Buffalo (1981–1986)
Director, Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital (1972–1981)
Visiting Scientist, Mario Negri Institute for Pharmacology, Italy (1978–1979)
Associate Professor of Pharmaceutics, Pharmaceutical Sciences, University at Buffalo (1974–1977)
Assistant Professor of Pharmaceutics, Pharmaceutical Sciences, University at Buffalo (1972–1974)
Assistant Professor of Pharmacology, Pharmacology, Boston University School of Medicine, Boston University School of Medicine (1970–1972)
Research Associate, Boston Collaborative Drug Surveillance Program, Boston University, Boston University Medical Center (1969–1972)
Research Pharmacologist, Veterans Administration Hospital Boston (1969–1972)
Research Assistant Dept. of Pharmaceutics, University at Buffalo (1962–1969)
Pharmacist, Soby's Pharmacy (1966–1968)
Hospital Pharmacist, Children's Hospital of Buffalo (1962–1966)

See all (7 more)

Awards and Honors:

AAPS Distinguished Pharmaceutical Scientist Award (2020)
Lewis B. Sheiner Pharmacometrics Award, ISoP (2019)
ASCPT Oscar B. Hunter Career Award (2018)
ASCPT/FDA William Abrams Lecture Award (2017)
Fellow, International Society of Pharmacometrics (2016)
Advisor: AAPS Graduate Student Award in PPDM - Xu Zhu and Xi (Cindy) Chen (2015)
Doctor Honoris Causae, University of Paris Descartes (2015)
Collegium of Eminent Scientists, Kosciuszko Foundation (2015)
ASCPT Sheiner-Beal Pharmacometrics Award (2013)
Advisor: AAPS Graduate Student Award in PPDM - Hoi Kei Lon (2012)
Distinguished Investigator Award ACCP (2012)
ACoP Leadership Award (2011)
AAPS Meritorious Manuscript Award (2008)
Paul Ehrlich Magic Bullet Lifetime Achievement Award (2008)
UB Distinguished Professor (2007)
Swintosky Distinguished Lecturer - UKY (2006)
Volwiler Research Achievement Award - AACP (2005)
MERIT Award - NIH (2005)
Roland T. Lakey Award Lecture - WS (2003)
ISI Most Highly Cited List in Pharmacology (2003)
Chancellor‘s Award for Research -UB (2003)
Sustained Achievement Award - UB (2002)
John G. Wagner Lectureship - UM (1999)
Research Achievement Award - PPDM, AAPS (1998)
Kosciusko Award - Buffalo (1996)
Distinguished Service Award - ACCP (1989)
Russell R. Miller Award - ACCP (1988)
Doctor Honoris Causae, Jagiellonian University, Krakow (1987)
Citizen of the Year - Buffalo (1987)
Rawls-Palmer Award - ASCPT (1987)
Fellow- AAPS (1986)
Fellow - ACCP (1986)
Fellow - AAAS (1985)
Rorer Award - AJG (1980)
Fellow - ACS (1980)
Fulbright-Hays Award to lecture/research in Milan, Italy (1978)

Research Expertise:

Pharmacodynamics: Pharmacogenomics of diverse effects of corticosteroids and the development of models of receptor/gene-mediated responses
Pharmacokinetics and Pharmacodynamics: Theoretical, basic, and clinical aspects of the PK/PD of immunosuppressive agents including corticosteroids, sirolimus, and tacrolimus

Grants and Sponsored Research:

August 2015–August 2019
Buffalo Clinical and Translational Research Center Clinical and Translational Science Award(CTSA)
National Center for Advancing Translational Sciences (NCATS)/National Institutes of Health
Role: Co-Investigator
$20,000,000
July 2015–June 2019
Corticosteroid Pharmacokinetics and Pharmacodynamics
NIH/NIGMS
Role: Principal Investigator
$2,392,890
September 2014–August 2017
Physiologically-Based Pharmacokinetic Model for Drugs Encapsulated into Liposomes
NIH/FDA
Role: Co-Investigator
$639,400
September 2011–August 2016
Molecular and Clinical Pharmacology of Retinopathy of Prematurity
NIH/NICHHD
Role: Co-Investigator
$79,020
June 2012–August 2013
Pharmacokinetics and Relative Bioavailability of Liquid Formulation of Hydroxyurea in Pediatric Patients with Sickle Cell Anemia
Duke University
Role: Principal Investigator
$19,439

Patents:

Novel Method of Treatment (1999)

Journal Articles:

Jeong YS, Jusko WJ. Meta-Assessment of Metformin Absorption and Disposition Pharmacokinetics in Nine Species. Pharmaceuticals (Basel). 2021; 14(6).
Krzyzanski W, Milad MA, Jobe AH, Peppard T, Bies RR, Jusko WJ. Population pharmacodynamic modeling of intramuscular and oral dexamethasone and betamethasone effects on six biomarkers with circadian complexities in Indian women. J Pharmacokinet Pharmacodyn. 2021; 48(3).
Acevedo A, Mavroudis PD, DuBois D, Almon RR, Jusko WJ, Androulakis IP. Pathway-level analysis of genome-wide circadian dynamics in diverse tissues in rat and mouse. J Pharmacokinet Pharmacodyn. 2021; 48(3).
Lin Q, Qian Z, Jusko WJ, Mager DE, Ma WW, Straubinger RM. Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation. J Pharmacol Exp Ther. 2021; 377(3).
Mavroudis PD, Jusko WJ. Mathematical modeling of mammalian circadian clocks affecting drug and disease responses. J Pharmacokinet Pharmacodyn. 2021; 48(3).
Song D, Jusko WJ. Across-species meta-analysis of dexamethasone pharmacokinetics utilizing allometric and scaling modeling approaches. Biopharm Drug Dispos. 2021; 42(5).
Krzyzanski W, Milad MA, Jobe AH, Peppard T, Bies RR, Jusko WJ. Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women. J Pharmacokinet Pharmacodyn. 2021; 48(2).
Liu X, Jusko WJ. Physiologically Based Pharmacokinetics of Lysosomotropic Chloroquine in Rat and Human. J Pharmacol Exp Ther. 2021; 376(2).
Li X, DuBois DC, Almon RR, Jusko WJ. Physiologically Based Pharmacokinetic Modeling Involving Nonlinear Plasma and Tissue Binding: Application to Prednisolone and Prednisone in Rats. J Pharmacol Exp Ther. 2020; 375(2).
Jusko WJ, Molins EAG, Ayyar VS. Seeking Nonspecific Binding: Assessing the Reliability of Tissue Dilutions for Calculating Fraction Unbound. Drug Metab Dispos. 2020; 48(10).
Li X, Conklin LS, van den Anker J, Hoffman EP, Clemens PR, Jusko WJ. Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy. J Clin Pharmacol. 2020; 60(10).
Acevedo A, DuBois D, Almon RR, Jusko WJ, Androulakis IP. Modeling Pathway Dynamics of the Skeletal Muscle Response to Intravenous Methylprednisolone (MPL) Administration in Rats: Dosing and Tissue Effects. Front Bioeng Biotechnol. 2020; 8.
Ramanadhan S, Jusko WJ, Edelman A. Pharmacokinetics of Hormonal Contraception in Individuals with Obesity: a Review. Curr Obstet Gynecol Rep. 2020; 9(2).
Yu R, Li X, DuBois DC, Almon RR, Cao Y, Jusko WJ. Interactions of Tofacitinib and Dexamethasone on Lymphocyte Proliferation. Pharm Res. 2020; 37(6).
Elmeliegy M, Den Haese J, Talati C, Wetzler M, Jusko WJ. Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia. Cancer Chemother Pharmacol. 2020; 86(3).
Song D, Sun L, DuBois DC, Almon RR, Meng S, Jusko WJ. Physiologically Based Pharmacokinetics of Dexamethasone in Rats. Drug Metab Dispos. 2020; 48(9).
Chen X, Song D, Nakada S, Qiu J, Iwamoto K, Chen RH, Lim YP, Jusko WJ, Stonestreet BS. Pharmacokinetics of Inter-Alpha Inhibitor Proteins and Effects on Hemostasis After Hypoxic-Ischemic Brain Injury in Neonatal Rats. Curr Pharm Des. 2020; 26(32).
Ayyar VS, Jusko WJ. Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids. Pharmacol Rev. 2020; 72(2).
Ayyar VS, Song D, DuBois DC, Almon RR, Jusko WJ. Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part I: Determination and Prediction of Dexamethasone and Methylprednisolone Tissue Binding in the Rat. J Pharmacol Exp Ther. 2019; 370(2).
Ayyar VS, DuBois DC, Nakamura T, Almon RR, Jusko WJ. Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part II: Sex Differences in Methylprednisolone Pharmacokinetics and Corticosterone Suppression. J Pharmacol Exp Ther. 2019; 370(2).
Ayyar VS, DuBois DC, Almon RR, Jusko WJ. Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part III: Estrous Cycle and Estrogen Receptor-Dependent Antagonism of Glucocorticoid-Induced Leucine Zipper (GILZ) Enhancement by Corticosteroids. J Pharmacol Exp Ther. 2019; 370(2).
Yu R, Song D, DuBois DC, Almon RR, Jusko WJ. Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats. AAPS J. 2019; 21(5).
Mavroudis PD, Ayyar VS, Jusko WJ. ATLAS mPBPK: a MATLAb-based tool for modeling and Simulation of minimal Physiologically Based PharmacoKinetic models. CPT Pharmacometrics Syst Pharmacol. 2019.
Natavio M, Stanczyk FZ, Molins EAG, Nelson A, Jusko WJ. Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. Contraception. 2019; 99(5).
Acevedo A, Berthel A, DuBois D, Almon RR, Jusko WJ, Androulakis IP. Pathway-Based Analysis of the Liver Response to Intravenous Methylprednisolone Administration in Rats: Acute Versus Chronic Dosing. Gene Regul Syst Bio. 2019; 13.
Luo D, Westhoff CL, Edelman AB, Natavio M, Stanczyk FZ, Jusko WJ. Altered pharmacokinetics of combined oral contraceptives in obesity - multistudy assessment. Contraception. 2019; 99(4).
Mavroudis PD, van den Anker J, Conklin LS, Damsker JM, Hoffman EP, Nagaraju K, Clemens PR, Jusko WJ. Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy. J Clin Pharmacol. 2019.
Ayyar VS, Krzyzanski W, Jusko WJ. Indirect pharmacodynamic models for responses with circadian removal. J Pharmacokinet Pharmacodyn. 2019; 46(1).
Luo D, Carter KA, Molins EAG, Straubinger NL, Geng J, Shao S, Jusko WJ, Straubinger RM, Lovell JF. Pharmacokinetics and pharmacodynamics of liposomal chemophototherapy with short drug-light intervals. J Control Release. 2019; 297.
Ayyar VS, Sukumaran S, DuBois DC, Almon RR, Jusko WJ. Modeling Corticosteroid Pharmacogenomics and Proteomics in Rat Liver. J Pharmacol Exp Ther. 2018; 367(1).
Zhu X, Trueman S, Straubinger RM, Jusko WJ. Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts. J Pharmacokinet Pharmacodyn. 2018; 45(5).
Li X, Jusko WJ, Cao Y. Role of Interstitial Fluid Turnover on Target Suppression by Therapeutic Biologics Using a Minimal Physiologically Based Pharmacokinetic Model. J Pharmacol Exp Ther. 2018; 367(1).
Zhu X, Shen X, Qu J, Straubinger RM, Jusko WJ.. Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells. CPT Pharmacometrics Syst Pharmacol.. 2018.
Song D, Dubois DC, Almon RR, Jusko WJ. Modeling Sex Differences in Anti-inflammatory Effects of Dexamethasone in CIA Rats. Pharmaceutical Research. 2018; 35(203).
Ayyar VS, Sukumaran S, DuBois DC, Almon RR, Qu J, Jusko WJ. Receptor/gene/protein-mediated signaling connects methylprednisolone exposure to metabolic and immune-related pharmacodynamic actions in liver. J Pharmacokinet Pharmacodyn. 2018; 45(4).
Mavroudis PD, DuBois DC, Almon RR, Jusko WJ. Modeling circadian variability of core-clock and clock-controlled genes in four tissues of the rat. PLoS One. 2018; 13(6).
Molins EAG, Jusko WJ. Assessment of Three-Drug Combination Pharmacodynamic Interactions in Pancreatic Cancer Cells. AAPS J. 2018; 20(5).
Mavroudis PD, DuBois DC, Almon RR, Jusko WJ. Daily variation of gene expression in diverse rat tissues. PLoS One. 2018; 13(5).
Chen X, Jiang X, Doddareddy R, Geist B, McIntosh T, Jusko WJ, Zhou H, Wang W. Development and Translational Application of a Minimal Physiologically Based Pharmacokinetic Model for a Monoclonal Antibody against Interleukin 23 (IL-23) in IL-23-Induced Psoriasis-Like Mice. J Pharmacol Exp Ther. 2018; 365(1).
McLaughlin MJ, He Y, Brunstrom-Hernandez J, Thio LL, Carleton BC, Ross CJD, Gaedigk A, Lewandowski A, Dai H, Jusko WJ, Leeder JS. Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy. PM R. 2018; 10(3).
Zhu X, Shen X, Qu J, Straubinger RM, Jusko WJ. Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells. Front Pharmacol. 2018; 9.
Ayyar VS, DuBois DC, Almon RR, Jusko WJ. Mechanistic Multi-Tissue Modeling of Glucocorticoid-Induced Leucine Zipper Regulation: Integrating Circadian Gene Expression with Receptor-Mediated Corticosteroid Pharmacodynamics. J Pharmacol Exp Ther. 2017; 363(1).
Li X, DuBois DC, Song D, Almon RR, Jusko WJ, Chen X. Modeling Combined Immunosuppressive and Anti-inflammatory Effects of Dexamethasone and Naproxen in Rats Predicts the Steroid-Sparing Potential of Naproxen. Drug Metab Dispos. 2017; 45(7).
Chen X, DuBois DC, Almon RR, Jusko WJ. Interrelationships between Infliximab and Recombinant Tumor Necrosis Factor-Î± in Plasma Using Minimal Physiologically Based Pharmacokinetic Models. Drug Metab Dispos. 2017; 45(7).
Chen X, DuBois DC, Almon RR, Jusko WJ. Characterization and Interspecies Scaling of rhTNF-Î± Pharmacokinetics with Minimal Physiologically Based Pharmacokinetic Models. Drug Metab Dispos. 2017; 45(7).
Nie J, DuBois DC, Xue B, Jusko WJ, Almon RR. Effects of High-Fat Feeding on Skeletal Muscle Gene Expression in Diabetic Goto-Kakizaki Rats. Gene Regul Syst Bio. 2017; 11.
Ayyar VS, Almon RR, DuBois DC, Sukumaran S, Qu J, Jusko WJ. Functional proteomic analysis of corticosteroid pharmacodynamics in rat liver: Relationship to hepatic stress, signaling, energy regulation, and drug metabolism. J Proteomics. 2017.
Kamisoglu K, Acevedo A, Almon RR, Coyle S, Corbett S, Dubois DC, Nguyen TT, Jusko WJ, Androulakis IP. Understanding Physiology in the Continuum: Integration of Information from Multiple -Omics Levels. Front Pharmacol. 2017; 8.
Li X, DuBois DC, Almon RR, Jusko WJ. Modeling Sex Differences in Pharmacokinetics, Pharmacodynamics, and Disease Progression Effects of Naproxen in Rats with Collagen-Induced Arthritis. Drug Metab Dispos. 2017.
Li X, DuBois DC, Almon RR, Jusko WJ. Effect of Disease-Related Changes in Plasma Albumin on the Pharmacokinetics of Naproxen in Male and Female Arthritic Rats. Drug Metab Dispos. 2017.
Koch G, Jusko WJ, Schropp J. Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases. J Pharmacokinet Pharmacodyn. 2017; 44(1).
Koch G, Jusko WJ, Schropp J. Target-mediated drug disposition with drug-drug interaction, Part I: single drug case in alternative formulations. J Pharmacokinet Pharmacodyn. 2017; 44(1).
Vali P, Chandrasekharan PK, Rawat M, Gugino S, Koenigsknecht C, Helman J, Jusko WJ, Mathew B, Berkelhamer SK, Nair J, Wyckoff MH, Lakshminrusimha S. Evaluation of Timing and Route of Epinephrine in a Neonatal Model of Asphyxial Arrest. J Am Heart Assoc. 2017; 6(2).
Jusko WJ. Clarification of contraceptive drug pharmacokinetics in obesity. Contraception. 2017; 95(1).
Jusko WJ. Perspectives on variability in pharmacokinetics of an oral contraceptive product. Contraception. 2017; 95(1).
Miao X, Koch G, Ait-Oudhia S, Straubinger RM, Jusko WJ. Pharmacodynamic modeling of cell cycle effects for gemcitabine and trabectedin combinations in pancreatic cancer cells Front Pharmacol. 2016; 7.
Koch G, Schropp J, Jusko WJ. Assessment of non-linear combination effect terms for drug-drug interactions. J Pharmacokinet Pharmacodyn. 2016; 43(5).
Rao R, DuBois D, Almon R, Jusko WJ, Androulakis IP. Mathematical modeling of the circadian dynamics of the neuroendocrine-immune network in experimentally induced arthritis. Am J Physiol Endocrinol Metab. 2016; 311(2).
Chen X, Jiang X, Jusko WJ, Zhou H, Wang W. Minimal physiologically-based pharmacokinetic (mPBPK) model for a monoclonal antibody against interleukin-6 in mice with collagen-induced arthritis. J Pharmacokinet Pharmacodyn. 2016; 43(3).
Miao X, Koch G, Straubinger RM, Jusko WJ. Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells. Cancer Chemother Pharmacol. 2016; 77(1).
Yoo H, Iirola T, Vilo S, Manner T, Aantaa R, Lahtinen M, Scheinin M, Olkkola KT, Jusko WJ. Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects. Eur J Clin Pharmacol. 2015; 71(10).
Fung HL, Jusko WJ. Perspectives on the history and scientific contributions of Gerhard Levy. J Pharmacokinet Pharmacodyn. 2015; 42(5).
Zhu X, Straubinger RM, Jusko WJ. Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. J Pharmacokinet Pharmacodyn. 2015; 42(5).
Zhao J, Cao Y, Jusko WJ. Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model. Pharm Res. 2015; 32(10).
Lon HK, DuBois DC, Earp JC, Almon RR, Jusko WJ. Modeling effects of dexamethasone on disease progression of bone mineral density in collagen-induced arthritic rats. Pharmacol Res Perspect. 2015; 3(5).
Xue B, Nie J, Wang X, DuBois DC, Jusko WJ, Almon RR. Effects of High Fat Feeding on Adipose Tissue Gene Expression in Diabetic Goto-Kakizaki Rats. Gene Regul Syst Bio. 2015; 9.
Estepp JH, Melloni C, Thornburg CD, Wiczling P, Rogers Z, Rothman JA, Green NS, Liem R, Brandow AM, Crary SE, Howard TH, Morris MH, Lewandowski A, Garg U, Jusko WJ, Neville KA. Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. J Clin Pharmacol. 2015.
Chen X, DuBois DC, Almon RR, Jusko WJ. Biodistribution of etanercept to tissues and sites of inflammation in arthritic rats. Drug Metab Dispos. 2015; 43(6).
Ayyar VS, Almon RR, Jusko WJ, DuBois DC. Quantitative tissue-specific dynamics of in vivo GILZ mRNA expression and regulation by endogenous and exogenous glucocorticoids. Physiol Rep. 2015; 3(6).
Grimsrud KN, Ait-Oudhia S, Durbin-Johnson BP, Rocke DM, Mama KR, Rezende ML, Stanley SD, Jusko WJ. Pharmacokinetic and pharmacodynamic analysis comparing diverse effects of detomidine, medetomidine, and dexmedetomidine in the horse: a population analysis. J Vet Pharmacol Ther. 2015; 38(1).
Kamisoglu K, Sukumaran S, Nouri-Nigjeh E, Tu C, Li J, Shen X, Duan X, Qu J, Almon RR, DuBois DC, Jusko WJ, Androulakis IP. Tandem analysis of transcriptome and proteome changes after a single dose of corticosteroid: a systems approach to liver function in pharmacogenomics. OMICS. 2015; 19(2).
Cao Y, Jusko WJ. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model. J Pharmacokinet Pharmacodyn. 2014; 41(6).
Wang X, DuBois DC, Sukumaran S, Ayyar V, Jusko WJ, Almon RR. Variability in Zucker diabetic fatty rats: differences in disease progression in hyperglycemic and normoglycemic animals. Diabetes Metab Syndr Obes. 2014; 7.
Wang X, DuBois DC, Cao Y, Jusko WJ, Almon RR. Diabetes disease progression in Goto-Kakizaki rats: effects of salsalate treatment. Diabetes Metab Syndr Obes. 2014; 7.
Nouri-Nigjeh E, Sukumaran S, Tu C, Li J, Shen X, Duan X, DuBois DC, Almon RR, Jusko WJ, Qu J. Highly multiplexed and reproducible ion-current-based strategy for large-scale quantitative proteomics and the application to protein expression dynamics induced by methylprednisolone in 60 rats. Anal Chem. 2014; 86(16).
Cao Y, Jusko WJ. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2014; 41(4).
Nguyen TT, Almon RR, Dubois DC, Sukumaran S, Jusko WJ, Androulakis IP. Tissue-specific gene expression and regulation in liver and muscle following chronic corticosteroid administration. Gene Regul Syst Bio. 2014; 8.
Fang J, Sukumaran S, Dubois DC, Almon RR, Jusko WJ. Meta-modeling of methylprednisolone effects on glucose regulation in rats. PLoS One. 2013; 8(12).
Lon HK, Liu D, DuBois DC, Almon RR, Jusko WJ. Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach. J Pharmacokinet Pharmacodyn. 2013; 40(6).
Cao Y, Balthasar JP, Jusko WJ. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2013; 40(5).
Jusko WJ. Moving from basic toward systems pharmacodynamic models. J Pharm Sci. 2013; 102(9).
Hamed SS, Straubinger RM, Jusko WJ. Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells. Cancer Chemother Pharmacol. 2013; 72(3).
Liu D; Lon H; Wang Y; Dubois DC; Almon RR; Jusko WJ. Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats. Biopharmaceutics & Drug Disposition. 2013; 34.
Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW, Jusko WJ, Ma W. Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemother Pharmacol. 2013; 71(5).
Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW, Jusko WJ, Ma W. Physiologically based pharmacokinetic models for everolimus and sorafenib in mice. Cancer Chemother Pharmacol. 2013.
Pawaskar DK, Straubinger RM, Fetterly GJ, Ma WW, Jusko WJ, Ma W. Interactions of everolimus and sorafenib in whole blood lymphocyte proliferation. Pharm Res. 2013; 30(3).
Dubois DC; Sukumaran S; Jusko WJ; Almon RR. Evidence for a Glucocorticoid Receptor Beta Splice Variant in the Rat and Its Physiological Regulation in Liver Steroids. Steroids. 2013; 78.
Fang J; Landersdorfer CB; Cirincione B; Jusko WJ. Study Reanalysis Using a Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Pramlintide in Subjects with Type 1 Diabetes. AAPSJ. 2013; 15.
Pawaskar DK, Straubinger RM, Fetterly GJ, Ma WW, Jusko WJ, Ma W. Interactions of everolimus and sorafenib in pancreatic cancer cells. AAPS J. 2013; 15(1).
Cao Y, Jusko WJ. Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2012; 39(6).
Almon RR, Dubois DC, Sukumaran S, Wang X, Xue B, Nie J, Jusko WJ. Effects of high fat feeding on liver gene expression in diabetic goto-kakizaki rats. Gene Regul Syst Bio. 2012; 6.
Sukumaran S; Lepist E; Dubois DC; Almon RR; Jusko WJ. Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone Effects on iNOS mRNA Expression and Nitric Oxide During LPSInduced Inflammation in Rats. Pharmaceutical Research. 2012; 29.
Cao Y; Dubois DC; Almon RR; Jusko WJ. Pharmacokinetics of salsalate and salicylic acid in normal and diabetic rats. Biopharmaceutics & Drug Disposition. 2012; 33.
Jusko WJ. Use of Pharmacokinetic Data Below Lower Limit of Quantitation Values. Pharmaceutical Research. 2012; 29.
Gao W, Jusko WJ. Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki rats. J Pharmacol Exp Ther. 2012; 341(3).
Gao W, Jusko WJ. Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. Drug Metab Dispos. 2012; 40(5).
Cao Y, Gao W, Jusko WJ. Pharmacokinetic/pharmacodynamic modeling of GLP-1 in healthy rats. Pharm Res. 2012; 29(4).
Landersdorfer CB; He Y; Jusko WJ. Mechanism-Based Population Modelling of the Effects of Vildagliptin on GLP-1, Glucose and Insulin in Patients with Type 2 Diabetes. British Journal of Clinical Pharmacology. 2012; 73.
Landersdorfer CB, He YL, Jusko WJ. Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV. Br J Clin Pharmacol. 2012; 73(3).
Lon HK, Liu D, Jusko WJ. Pharmacokinetic/pharmacodynamic modeling in inflammation. Crit Rev Biomed Eng. 2012; 40(4).
Sukumaran S, Dubois DC, Jusko WJ, Almon RR. Glucocorticoid effects on adiponectin expression. Vitam Horm. 2012; 90.
Liu D, Lon HK, Dubois DC, Almon RR, Jusko WJ. Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis. J Pharmacokinet Pharmacodyn. 2011; 38(6).
Cao Y, Dubois DC, Sun H, Almon RR, Jusko WJ. Modeling diabetes disease progression and salsalate intervention in Goto-Kakizaki rats. J Pharmacol Exp Ther. 2011; 339(3).
MA,ller JB; Jusko WJ; Gao W; Hansen T; Pedersen O; Holst JJ; Overgaard RV; Madsen H; Ingwersen SH. Mechanism-Based Population Modelling for Assessment of L-Cell Function Based on Total GLP-1 Response Following an Oral Glucose Tolerance Test. Journal of Pharmacokinetics and Pharmacodynamics. 2011; 38.
Bai JP, Bell R, Buckman S, Burckart GJ, Eichler HG, Fang KC, Goodsaid FM, Jusko WJ, Lesko LL, Meibohm B, Patterson SD, Puig O, Smerage JB, Snider BJ, Wagner JA, Wang J, Walton MK, Weiner R. Translational biomarkers: from preclinical to clinical a report of 2009 AAPS/ACCP Biomarker Workshop. AAPS J. 2011; 13(2).
Sukumaran S, Jusko WJ, Dubois DC, Almon RR. Light-dark oscillations in the lung transcriptome: implications for lung homeostasis, repair, metabolism, disease, and drug action. J Appl Physiol (1985). 2011; 110(6).
Fang J, DuBois DC, He Y, Almon RR, Jusko WJ. Dynamic modeling of methylprednisolone effects on body weight and glucose regulation in rats. J Pharmacokinet Pharmacodyn. 2011; 38(3).
Scheff JD, Almon RR, Dubois DC, Jusko WJ, Androulakis IP. Assessment of pharmacologic area under the curve when baselines are variable. Pharm Res. 2011; 28(5).
Nie J; Bai B; Sukumaran S; Jusko WJ; Dubois DC; Almon RR. Differential Muscle Gene Expression as a Function of Disease Progression in Goto-Kakizaki Diabetic Rats. Molecular and Cellular Endocrinology. 2011; 338.
Sukumaran S; Jusko WJ; Dubois DC; Almon RR. MECHANISTIC MODELING OF THE EFFECTS OF GLUCOCORTICOIDS AND CIRCADIAN RHYTHMS ON ADIPOKINE EXPRESSION. J. Pharmacol. Exp. Ther.. 2011; 337.
Lon H; Liu D; Zhang Q; Dubois DC; Almon RR; Jusko WJ. Pharmacokinetic-Pharmacodynamic Disease Progression Model for Effect of Etanercept in Lewis Rats with Collagen-Induced Arthritis. Pharmaceutical Research. 2011; 28.
Xue B, Sukumaran S, Nie J, Jusko WJ, Dubois DC, Almon RR. Adipose tissue deficiency and chronic inflammation in diabetic Goto-Kakizaki rats. PLoS One. 2011; 6(2).
Gao W; Jusko WJ. Pharmacokinetic and Pharmacodynamic Modeling of Exendin-4 in Type 2 Diabetic Goto-Kakizaki Rats. THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2011; 336.
Gao W, Bihorel S, DuBois DC, Almon RR, Jusko WJ. Mechanism-based disease progression modeling of type 2 diabetes in Goto-Kakizaki rats. J Pharmacokinet Pharmacodyn. 2011; 38(1).
Scheff JD; Almon RR; Dubois DC; Jusko WJ; Androulakis IP. Assessment of Pharmacologic Area Under the Curve when Baselines are Variable. Pharmaceutical Research. 2011; 28.
Nie J; Dubois DC; Jusko WJ; Almon RR. Mechanistic Population Modeling of Diabetes Disease Progression in Goto-Kakizaki Rat Muscle. BIOPHARMACEUTICS & DRUG DISPOSITION. 2011; 32.
Sukumaran S; Xue B; Jusko WJ; Dubois DC; Almon RR. Circadian variations in gene expression in rat abdominal adipose tissue and relationship to physiology. Physiol Genomics. 2010; 42A.
Jusko WJ; Ziegler A; Chatenoud C; Waldmann H; Hale G; Rebello P; Al Bakir I; Bolam E; Wiczling P; Vandemeulebroucke E; Keymeulen B; Mathieu C. Pharmacokinetics and Antibody Responses to the CD3 Antibody Otelixizumab Used in the Treatment of Type 1 Diabetes. The Journal of Clinical Pharmacology. 2010; 50.
Ovacik MA, Sukumaran S, Almon RR, DuBois DC, Jusko WJ, Androulakis IP. Circadian signatures in rat liver: from gene expression to pathways. BMC Bioinformatics. 2010; 11.
Scheff JD; Almon RR; Dubois DC; Jusko WJ; Androulakis IP. A New Symbolic Representation for the Identification of Informative Genes in Replicated Microarray Experiments. OMICS A Journal of Integrative Biology. 2010; 14.
Sukumaran S; Almon RR; Dubois DC; Jusko WJ. Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. Advanced Drug Delivery Reviews. 2010; 62.
Nguyen TT; Almon RR; Dubois DC; Jusko WJ; Androulakis IP. Comparative Analysis of Acute and Chronic Corticosteroid Pharmacogenomic Effects in Rat Liver: Transcriptional Dynamics and Regulatory Structures. BMC Bioinformatics. 2010; 11.
Landersdorfer CB; Jusko WJ. Pharmacokinetic/Pharmacodynamic Modeling of Glucose Clamp Effects of Inhaled and Subcutaneous Insulin in Healthy Volunteers and Diabetic Patients. Drug Metab. Pharmacokinet.. 2010; 25.
Findling RL, Landersdorfer CB, Kafantaris V, Pavuluri M, McNamara NK, McClellan J, Frazier JA, Sikich L, Kowatch R, Lingler J, Faber J, Taylor-Zapata P, Jusko WJ. First-dose pharmacokinetics of lithium carbonate in children and adolescents. J Clin Psychopharmacol. 2010; 30(4).
Ghoshal S; Rao I; Earp JC; Jusko WJ; Wetzler M. Down-regulation of heat shock protein 70 improves arsenic trioxide and 17-DMAG effects on constitutive signal transducer and activator of transcription 3 activity. Cancer Chemotherapy Pharmacology. 2010; 66.
Nguyen TT; Almon RR; Dubois DC; Jusko WJ; Androulakis IP. Importance of replication in analyzing time-series gene expression data: Corticosteroid dynamics and circadian patterns in rat liver. BMC Bioinformatics. 2010; 11.
Wiczling P; Rosenzweig M; Vaickus L; Jusko WJ. Pharmacokinetics and Pharmacodynamics of a Chimeric/Humanized Anti-CD3 Monoclonal Antibody, Otelixizumab (TRX4), in Subjects with Psoriasis and with Type 1 Diabetes Mellitus. Journal of Clinical Pharmacology. 2010; 50.
Bulitta JB, Yang JC, Yohonn L, Ly NS, Brown SV, D'Hondt RE, Jusko WJ, Forrest A, Tsuji BT. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother. 2010; 54(5).
Freishtat RJ; Nagaraju K; Jusko WJ; Hoffman EP. Glucocorticoid Efficacy in Asthma: Is Improved Tissue Remodeling Upstream of Anti-Inflammation. Journal of Investigative Medicine. 2010; 58.
Khinkis LA, Krzyzanski W, Jusko WJ, Greco WR. D-optimal designs for parameter estimation for indirect pharmacodynamic response models. J Pharmacokinet Pharmacodyn. 2009; 36(6).
Woo S, Pawaskar D, Jusko WJ. Methods of utilizing baseline values for indirect response models. J Pharmacokinet Pharmacodyn. 2009; 36(5).
Cho H; Blum RA; Sunderland T; Cooper GJ; Jusko WJ. Pharmacokinetic and Pharmacodynamic Modeling of a Copper-Selective Chelator (TETA) in Healthy Adults. The Journal of Clinical Pharmacology. 2009; 49.
Yang EH, Almon RR, Dubois DC, Jusko WJ, Androulakis IP. Identification of global transcriptional dynamics. PLoS One. 2009; 4(7).
Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer Chemother Pharmacol. 2009; 63(6).
Almon RR; Dubois DC; Lai W; Xue B; Nie J; Jusko WJ. Gene expression analysis of hepatic roles in cause and development of diabetes in Goto-Kakizaki rats.. J Endocrinol. 2009; 200.
Landersdorfer CB; Dubois DC; Almon RR; Jusko WJ. Mechanism-based modeling of nutritional and leptin influences on growth in normal and type 2 diabetic rats.. J Pharmacol Exp Ther. 2009; 328.
Bulitta JB; Ly NS; Yang JC; Forrest A; Jusko WJ; Tsuji BT. Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa. Antimicrob. Ag. Chemother.. 2009; 53.
Earp JC; Dubois DC; Almon RR; Jusko WJ. Quantitative dynamic models of arthritis progression in the rat.. Pharm Res. 2009; 26.
Mager DE, Woo S, Jusko WJ. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet. 2009; 24(1).
Jin JY, Jusko WJ. Pharmacodynamics of glucose regulation by methylprednisolone. I. Adrenalectomized rats. Biopharm Drug Dispos. 2009; 30(1).
Jin JY, Jusko WJ. Pharmacodynamics of glucose regulation by methylprednisolone. II. normal rats. Biopharm Drug Dispos. 2009; 30(1).
Rohatagi S; Carrothers TJ; Jin J; Jusko WJ; Khariton T; Walker J; Truitt K; Salazar DE. Model-Based Development of a PPAR-gamma Agonist, Rivoglitazone, to Aid Dose Selection and Optimize Clinical Trial Designs. J Clin Pharmacol. 2008; 48.
Yao Z; Dubois DC; Almon RR; Jusko WJ. Pharmacodynamic/Pharmacogenomic Modeling of Insulin Resistance Genes in Rat Muscle After Methylprednisolone Treatment: Exploring Regulatory Signaling Cascades. Gene Reg. Sys. Biol.. 2008; 2.
Almon RR; Yang E; Lai W; Androulakis IP; Ghimbovschi S; Hoffman EP; Jusko WJ; Dubois DC. Relationships between circadian rhythms and modulation of gene expression by glucocorticoids in skeletal muscle.. Am J Physiol Regul Integr Comp Physiol.. 2008; 295.
Almon RR; Yang E; Lai W; Androulakis IP; Dubois DC; Jusko WJ. Circadian variations in rat liver gene expression: relationships to drug actions.. J Pharmacol Exp Ther. 2008; 326.
Earp JC, Pyszczynski NA, Molano DS, Jusko WJ. Pharmacokinetics of dexamethasone in a rat model of rheumatoid arthritis. Biopharm Drug Dispos. 2008; 29(6).
Earp JC; Dubois DC; Molan DS; Pyszcznski NA; Keller CE; Almon RR; Jusko WJ. Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats. J. Pharmacol. Exp. Ther.. 2008; 326.
Earp JC; Dubois DC; Molano DS; Pyszczynski NA; Almon RR; Jusko WJ. Modeling corticosteroid effects in a rat model of rheumatoid arthritis II: mechanistic pharmacodynamic model for dexamethasone effects in Lewis rats with collagen-induced arthritis.. J Pharmacol Exp Ther.. 2008; 326.
Yao Z, DuBois DC, Almon RR, Jusko WJ. Pharmacokinetic/pharmacodynamic modeling of corticosterone suppression and lymphocytopenia by methylprednisolone in rats. J Pharm Sci. 2008; 97(7).
Woo S, Krzyzanski W, Jusko WJ. Pharmacodynamic model for chemotherapy-induced anemia in rats. Cancer Chemother Pharmacol. 2008; 62(1).
Hazra A, Pyszczynski NA, DuBois DC, Almon RR, Jusko WJ. Modeling of corticosteroid effects on hepatic low-density lipoprotein receptors and plasma lipid dynamics in rats. Pharm Res. 2008; 25(4).
Yao Z, Hoffman EP, Ghimbovschi S, Dubois DC, Almon RR, Jusko WJ. Mathematical modeling of corticosteroid pharmacogenomics in rat muscle following acute and chronic methylprednisolone dosing. Mol Pharm. 2008; 5(2).
Yang E; Almon RR; Dubois DC; Androulakis IP; Jusko WJ. Extracting global system dynamics of corticosteroid genomic effects in rat liver. J Pharmacol Exp Ther. 2008; 324.
Hazra A; Dubois DC; Almon RR; Snyder GS; Jusko WJ. Pharmacodynamic Modeling of Acute and Chronic Effects of Methylprednisolone on Hepatic Urea Cycle Genes in Rats. Gene Regulation and Systems Biology. 2008; 2.
Woo S; Krzyzanski W; Jusko WJ. Pharmacodynamic model for chemotherapy-induced anemia in rats. Cancer Chem. Pharmacol.. 2008; 62.
Woo S; Krzyzanski W; Duliege A; Stead RR; Jusko WJ. Population Pharmacokinetics and Pharmacodynamics of Peptidic Erythropoiesis Receptor Agonist (ERA) in Healthy Volunteers. J. Clin. Pharmacol.. 2008; 48.
Landersdorfer CB, Jusko WJ. Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. Clin Pharmacokinet. 2008; 47(7).
Hazra A; Pyszczynski NA; Dubois DC; Almon RR; Jusko WJ. Modeling receptor/gene-mediated effects of corticosteroids on hepatic tyrosine aminotransferase dynamics in rats: dual regulation by endogenous and exogenous corticosteroids. J Pharmacokinet Pharmacodyn. 2007; 34.
Woo S; Krzyzanski W; Jusko WJ. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J. Pharmacokin. Pharmacodyn.. 2007; 34.
Yao Z; Dubois DC; Almon RR; Jusko WJ. Pharmacokinetic/pharmacodynamic modeling of corticosterone suppression and lymphocytopenia by methylprednisolone in rats. J Pharm Sci. 2007; 97.
Hazra A; Dubois DC; Almon RR; Jusko WJ. Assessing the Dynamics of Nuclear Glucocorticoid-Receptor Complex: Adding Flexibility to Gene Expression Modeling. J. Pharmacokin. Pharmacodyn.. 2007; 34.
Hong Y; Mager DE; Blum RA; Jusko WJ. Population pharmacokinetic/pharmacodynamic modeling of systemic corticosteroid inhibition of whole blood lymphocytes: Modeling interoccasion pharmacodynamic variability. Pharm Res. 2007; 24.
Yang E, Simcha D, Almon RR, Dubois DC, Jusko WJ, Androulakis IP. Context specific transcription factor prediction. Ann Biomed Eng. 2007; 35(6).
Almon RR; Dubois DC; Yao Z; Hoffman EP; Ghimbovschi S; Jusko WJ. Microarray analysis of the temporal response of skeletal muscle to methylprednisolone: comparative analysis of two dosing regimens. Physiol Genomics. 2007; 30.
Yao Z; Zhao B; Hoffman EP; Ghimbovschi S; Dubois DC; Almon RR; Jusko WJ. Application of Scaling Factors in Simultaneous Modeling of Microarray Data from Diverse Chips. Pharm. Res.. 2007; 24.
Wetzler M, Earp JC, Brady MT, Keng MK, Jusko WJ. Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity--pharmacodynamic drug-drug interaction modeling. Clin Cancer Res. 2007; 13(7).
Almon RR; Dubois DC; Jusko WJ. A Microarray Analysis of the Temporal Response of Liver to Methylprednisolone: A Comparative Analysis of Two Dosing Regimens. Endocrinology. 2007; 148.
Hazra A, Krzyzanski W, Jusko WJ. Mathematical assessment of properties of precursor-dependent indirect pharmacodynamic response models. J Pharmacokinet Pharmacodyn. 2006; 33(6).
Krzyzanski W, Dmochowski J, Matsushima N, Jusko WJ. Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models. J Pharmacokinet Pharmacodyn. 2006; 33(5).
Meno-Tetang GM, Li H, Mis S, Pyszczynski N, Heining P, Lowe P, Jusko WJ. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos. 2006; 34(9).
Qu J, Jusko WJ, Straubinger RM. Utility of cleavable isotope-coded affinity-tagged reagents for quantification of low-copy proteins induced by methylprednisolone using liquid chromatography/tandem mass spectrometry. Anal Chem. 2006; 78(13).
Woo S; Krzyzanski W; Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats.. Journal of Pharmacology and Experimental Therapeutics. 2006; 319.
Yao Z, DuBois DC, Almon RR, Jusko WJ. Modeling circadian rhythms of glucocorticoid receptor and glutamine synthetase expression in rat skeletal muscle. Pharm Res. 2006; 23(4).
Samtani MN, Pyszczynski NA, Dubois DC, Almon RR, Jusko WJ. Modeling glucocorticoid-mediated fetal lung maturation: I. Temporal patterns of corticosteroids in rat pregnancy. J Pharmacol Exp Ther. 2006; 317(1).
Samtani MN, Pyszczynski NA, Dubois DC, Almon RR, Jusko WJ. Modeling glucocorticoid-mediated fetal lung maturation: II. Temporal patterns of gene expression in fetal rat lung. J Pharmacol Exp Ther. 2006; 317(1).
Yao Z; Krzyzanski W; Jusko WJ. Assessment of basic indirect pharmacodynamic response models with physiological limits.. Journal of Pharmacokinetics and Pharmacodynamics. 2006; 33.
Krzyzanski W; Woo S; Jusko WJ. Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans.. Journal of Pharmacokinetics and Pharmacodynamics. 2006; 33.
Hon YY, Jusko WJ, Zhou HH, Chen GL, Guo D, Zhou G, Spratlin VE, Jann MW. Endogenous histamine and cortisol levels in subjects with different histamine N-methyltransferase C314T genotypes : a pilot study. Mol Diagn Ther. 2006; 10(2).
Gordi T, Xie R, Jusko WJ. Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin. Br J Clin Pharmacol. 2005; 60(6).
Almon RR, Lai W, DuBois DC, Jusko WJ. Corticosteroid-regulated genes in rat kidney: mining time series array data. Am J Physiol Endocrinol Metab. 2005; 289(5).
Samtani MN, Jusko WJ. Stability of dexamethasone sodium phosphate in rat plasma. Int J Pharm. 2005; 301(1-2).
Mager DE; Neuteboom B; Jusko WJ. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys. Pharm Res. 2005; 22.
Almon RR, Dubois DC, Jin JY, Jusko WJ. Temporal profiling of the transcriptional basis for the development of corticosteroid-induced insulin resistance in rat muscle. J Endocrinol. 2005; 184(1).
Samtani MN, Schwab M, Nathanielsz PW, Jusko WJ. Area/moment and compartmental modeling of pharmacokinetics during pregnancy: applications to maternal/fetal exposures to corticosteroids in sheep and rats. Pharm Res. 2004; 21(12).
Earp J, Krzyzanski W, Chakraborty A, Zamacona MK, Jusko WJ. Assessment of drug interactions relevant to pharmacodynamic indirect response models. J Pharmacokinet Pharmacodyn. 2004; 31(5).
Kamal MA, Jusko WJ. Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays. J Clin Pharmacol. 2004; 44(9).
Ramakrishnan R, Cheung WK, Wacholtz MC, Minton N, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol. 2004; 44(9).
Lepist EI, Jusko WJ. Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis. J Vet Pharmacol Ther. 2004; 27(4).
Lima JJ, Matsushima N, Kissoon N, Wang J, Sylvester JE, Jusko WJ. Modeling the metabolic effects of terbutaline in beta2-adrenergic receptor diplotypes. Clin Pharmacol Ther. 2004; 76(1).
Almon RR, DuBois DC, Piel WH, Jusko WJ. The genomic response of skeletal muscle to methylprednisolone using microarrays: tailoring data mining to the structure of the pharmacogenomic time series. Pharmacogenomics. 2004; 5(5).
Jin JY, DuBois DC, Almon RR, Jusko WJ. Receptor/gene-mediated pharmacodynamic effects of methylprednisolone on phosphoenolpyruvate carboxykinase regulation in rat liver. J Pharmacol Exp Ther. 2004; 309(1).
Samtani MN, Schwab M, Nathanielsz PW, Jusko WJ. Stabilization and HPLC analysis of betamethasone sodium phosphate in plasma. J Pharm Sci. 2004; 93(3).
Chen J, Zhao P, Massaro D, Clerch LB, Almon RR, DuBois DC, Jusko WJ, Hoffman EP. The PEPR GeneChip data warehouse, and implementation of a dynamic time series query tool (SGQT) with graphical interface. Nucleic Acids Res. 2004; 32(Datab).
Smith PF, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. The influence of St. John‘s wort on the pharmacokinetics and protein bindingof imatinib mesylate. Pharmacotherapy. 2004; 24(11).
Almon RR, DuBois DC, Pearson KE, Stephan DA, Jusko WJ. Gene arrays and temporal patterns of drug response: corticosteroid effects on rat liver. Funct Integr Genomics. 2003; 3(4).
Mager DE; Lin SX; Blum RA; Lates CD; Jusko WJ. Dose equivalency evaluation of major corticosteroids: Pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol. 2003; 43.
Almon RR, Chen J, Snyder G, DuBois DC, Jusko WJ, Hoffman EP. In vivo multi-tissue corticosteroid microarray time series available online at Public Expression Profile Resource (PEPR).. Pharmacogenomics. 2003; 4(6).
Jin JY, Almon RR, DuBois DC, Jusko WJ. Modeling of corticosteroid pharmacogenomics in rat liver using gene microarrays. J Pharmacol Exp Ther. 2003; 307(1).
Ramakrishnan R, Cheung WK, Farrell F, Joffee L, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys. J Pharmacol Exp Ther. 2003; 306(1).
Mager DE; Neuteboom B; Efthymiopoulos C; Munafo A; Jusko WJ. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta 1a in monkeys. J Pharmacol Exp Ther. 2003; 306.
Levy G; Mager DE; Cheung WK; Jusko WJ. Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. J Pharm Sci. 2003; 92.
Mager DE; Wyska E; Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Disp. 2003; 31.
Mager DE; Pyszczynski NA; Jusko WJ. Integrated QSPR - pharmacodynamic model of genomic effects of several corticosteroids. J Pharm Sci. 2003; 92.
Mager DE; Jusko WJ. Quantitative structure-pharmacokinetic/pharmacodynamic relationships of corticosteroids in man. J Pharm Sci. 2002; 91.
Mager DE; Jusko WJ. Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in man. Pharm Res. 2002; 19.
Krzyzanski W, Jusko WJ. Multiple-pool cell lifespan model of hematologic effects of anticancer agents. J Pharmacokinet Pharmacodyn. 2002; 29(4).
Magee MH, Blum RA, Lates CD, Jusko WJ. Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation. Br J Clin Pharmacol. 2002; 53(5).
Chakraborty A, Jusko WJ. Pharmacodynamic interaction of recombinant human interleukin-10 and prednisolone using in vitro whole blood lymphocyte proliferation. J Pharm Sci. 2002; 91(5).
Li H, Meno-Tetang GM, Chiba K, Arima N, Heining P, Jusko WJ. Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses. J Pharmacol Exp Ther. 2002; 301(2).
Ramakrishnan R, DuBois DC, Almon RR, Pyszczynski NA, Jusko WJ. Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. J Pharmacokinet Pharmacodyn. 2002; 29(1).
Ramakrishnan R, DuBois DC, Almon RR, Pyszczynski NA, Jusko WJ. Pharmacodynamics and pharmacogenomics of methylprednisolone during 7-day infusions in rats. J Pharmacol Exp Ther. 2002; 300(1).
Wyska E, Jusko WJ. Approaches to pharmacokinetic/ pharmacodynamic modeling during pregnancy. Semin Perinatol. 2001; 25(3).
Gobburu JV, Jusko WJ. Role of dosage regimen in controlling indirect pharmacodynamic responses. Adv Drug Deliv Rev. 2001; 46(1-3).
Krzyzanski W, Jusko WJ. Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition. J Pharmacokinet Pharmacodyn. 2001; 28(1).
Mager DE; Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001; 28.
Mager DE; Jusko WJ. Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther. 2001; 70.
Levy G, Zamacona MK, Jusko WJ. Developing compliance instructions for drug labeling. Clin Pharmacol Ther. 2000; 68(6).
Gabrielsson J, Jusko WJ, Alari L. Modeling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles. Biopharm Drug Dispos. 2000; 21(2).
Krzyzanski W, Chakraborty A, Jusko WJ. Algorithm for application of Fourier analysis for biorhythmic baselines of pharmacodynamic indirect response models. Chronobiol Int. 2000; 17(1).
Chow FS, Sharma A, Jusko WJ. Modeling interactions between adrenal suppression and T-helper lymphocyte trafficking during multiple dosing of methylprednisolone. J Pharmacokinet Biopharm. 1999; 27(6).
Krzyzanski W, Ramakrishnan R, Jusko WJ. Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm. 1999; 27(5).
Meno-Tetang GM, Hon YY, Van Wart S, Jusko WJ. Pharmacokinetic and pharmacodynamic interactions between dehydroepiandrosterone and prednisolone in the rat. Drug Metabol Drug Interact. 1999; 15(1).
Jusko WJ. Role of dosage regimen in controlling indirect pharmacodynamic responses. Adv Drug Deliv Rev. 1998; 33(3).
Mishina EV, Straubinger RM, Pyszczynski NA, Jusko WJ. Enhancement of tissue delivery and receptor occupancy of methylprednisolone in rats by a liposomal formulation. Pharm Res. 1993; 10(10).
Tornatore KM, Morse GD, Jusko WJ, Walshe JJ. Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. Transplantation. 1989; 48(6).
Sutfin TA, Perini GI, Molnar G, Jusko WJ. Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients.. J Clin Psychopharmacol. 1988; 8(1).
Kanarkowski R, Tornatore KM, D‘Ambrosio R, Gardner MJ, Jusko WJ. Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. Clin Pharmacol Ther. 1988; 43(1).
Morphy MA, Fava GA, Carson SW, Perini GI, Molnar G, Jusko WJ. The metyrapone test in schizophrenic patients and healthy subjects.. Neuropsychobiology. 1985; 14(1).
Perini GI, Fava GA, Morphy MA, Carson SW, Molnar G, Jusko WJ. The metyrapone test in affective disorders and schizophrenia II. Changes upon treatment.. J Affect Disord. 1984; 7(3-4).
Fava GA, Carson SW, Perini GI, Morphy MA, Molnar G, Jusko WJ. The metyrapone test in affective disorders and schizophrenia.. J Affect Disord. 1984; 6(3-4).
Perini GI, Fava GA, Morphy MA, Carson SW, Molnar G, Jusko WJ. The metyrapone test in manic patients and healthy subjects.. Pharmacopsychiatry. 1984; 17(3).
Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R. Effects of tobacco smoking and oral contraceptive use on theophylline disposition. Br J Clin Pharmacol. 1983; 16(3).
Milsap RL, George DE, Szefler SJ, Murray KA, Lebenthal E, Jusko WJ. Effect of inflammatory bowel disease on absorption and disposition of prednisolone.. Dig Dis Sci. 1983; 28(2).
Szefler SJ, Brenner M, Jusko WJ, Spector SL, Flesher KA, Ellis EF. Dose- and time-related effect of troleandomycin on methylprednisolone elimination.. Clin Pharmacol Ther. 1982; 32(2).
Szefler SJ, Ellis EF, Brenner M, Rose JQ, Spector SL, Yurchak AM, Andrews F, Jusko WJ. Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy.. J Allergy Clin Immunol. 1982; 69(5).
Tornatore KM, Kanarkowski R, McCarthy TL, Gardner MJ, Yurchak AM, Jusko WJ. Effect of chronic oral contraceptive steroids on theophylline disposition. Eur J Clin Pharmacol. 1982; 23(2).
Rose JQ, Nickelsen JA, Ellis EF, Middleton E, Jusko WJ. Prednisolone disposition in steroid-dependent asthmatic children.. J Allergy Clin Immunol. 1981; 67(3).
Rocci ML, Szefler SJ, Acara M, Jusko WJ. Prednisolone metabolism and excretion in the isolated perfused rat kidney.. Drug Metab Dispos. 1981; 9(3).
Szefler SJ, Rose JQ, Ellis EF, Spector SL, Green AW, Jusko WJ. The effect of troleandomycin on methylprednisolone elimination. J Allergy Clin Immunol. 1980; 66(6).
Rose JQ, Nickelsen JA, Middleton E, Yurchak AM, Park BH, Jusko WJ. Prednisolone disposition in steroid-dependent asthmatics.. J Allergy Clin Immunol. 1980; 66(5).
Hilligoss DM, Jusko WJ, Koup JR, Giacoia G. Factors affecting theophylline pharmacokinetics in premature infants with apnea. Dev Pharmacol Ther. 1980; 1(1).
Assael BM, Cavanna G, Jusko WJ, Marini A, Parini R, Sereni F, ViganÃ² A. Multiexponential elimination of gentamicin. A kinetic study during development. Dev Pharmacol Ther. 1980; 1(2-3).
Jusko WJ, Rose JQ. Monitoring prednisone and prednisolone. Ther Drug Monit. 1980; 2(2).
Jusko WJ, Gardner MJ, Mangione A, Schentag JJ, Koup JR, Vance JW. Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. J Pharm Sci. 1979; 68(11).
Sutfin TA, Jusko WJ. High-performance liquid chromatographic assay for imipramine, desipramine, and their 2-hydroxylated metabolites. J Pharm Sci. 1979; 68(6).
MacKichan JJ, Jusko WJ, Duffner PK, Cohen ME. Liquid-chromatographic assay of diazepam and its major metabolites in plasma.. Clin Chem. 1979; 25(6).
MacKichan JJ, Jusko WJ. Hydrocortisone stability in human feces. J Pharm Sci. 1979; 68(5).
Lima JJ, Conti DR, Goldfarb AL, Tilstone WJ, Golden LH, Jusko WJ. Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.. J Pharmacokinet Biopharm. 1979; 7(1).
Lima JJ, Goldfarb AL, Conti DR, Golden LH, Bascomb BL, Benedetti GM, Jusko WJ. Safety and efficacy of procainamide infusions.. Am J Cardiol. 1979; 43(1).
Plaut ME, Schentag JJ, Jusko WJ. Aminoglycoside nephrotoxicity: comparative assessment in critically ill patients.. J Med. 1979; 10(4).
DeVane CL, Wolin RE, Jusko WJ. Pharmacokinetic basis for predicting steady-state serum drug concentrations of imipramine from single dose data. Commun Psychopharmacol. 1979; 3(5).
Jusko WJ. Influence of cigarette smoking on drug metabolism in man. Drug Metab Rev. 1979; 9(2).
Rose JQ, Barron SA, Jusko WJ. Phenytoin disposition in smokers and nonsmokers. Int J Clin Pharmacol Biopharm. 1978; 16(11).
Schentag JJ, Cumbo TJ, Jusko WJ, Plaut ME. Gentamicin tissue accumulation and nephrotoxic reactions.. JAMA. 1978; 240(19).
Jusko WJ, Schentag JJ, Clark JH, Gardner M, Yurchak AM. Enhanced biotransformation of theophylline in marihuana and tobacco smokers.. Clin Pharmacol Ther. 1978; 24(4).
Owerbach J, Johnson NF, Bates TR, Pieniaszek HJ, Jusko WJ. High-performance liquid chromatographic assay of sulfapyridine and acetylsulfapyridine in biological fluids. J Pharm Sci. 1978; 67(9).
MacKichan JJ, Pyszczynski DR, Jusko WJ. Analysis and disposition of low dose oral propranolol. Res Commun Chem Pathol Pharmacol. 1978; 20(3).
Colburn WA, Schentag JJ, Jusko WJ, Gibaldi M. A model for the prospective identification of the prenephrotoxic state during gentamicin therapy. J Pharmacokinet Biopharm. 1978; 6(3).
Lima JJ, Conti DR, Goldfarb AL, Golden LH, Jusko WJ. Pharmacokinetic approach to intravenous procainamide therapy.. Eur J Clin Pharmacol. 1978; 13(4).
Mangione A, Imhoff TE, Lee RV, Shum LY, Jusko WJ. Pharmacokinetics of theophylline in hepatic disease.. Chest. 1978; 73(5).
Schentag JJ, Lasezkay G, Plaut ME, Jusko WJ, Cumbo TJ. Comparative tissue accumulation of gentamicin and tobramycin in patients.. J Antimicrob Chemother. 1978; 4 Sup.
Schentag JJ, Lasezkay G, Cumbo TJ, Plaut ME, Jusko WJ. Accumulation pharmacokinetics of tobramycin.. Antimicrob Agents Chemother. 1978; 13(4).
Gal P, Jusko WJ, Yurchak AM, Franklin BA. Theophylline disposition in obesity. Clin Pharmacol Ther. 1978; 23(4).
Jusko WJ. Role of tobacco smoking in pharmacokinetics. J Pharmacokinet Biopharm. 1978; 6(1).
Lima JJ, Jusko WJ. Determination of procainamide acetylator status. Clin Pharmacol Ther. 1978; 23(1).
Schentag JJ, Sutfin TA, Plaut ME, Jusko WJ. Early detection of aminoglycoside nephrotoxicity with urinary beta-2-microglobulin.. J Med. 1978; 9(3).
Schentag JJ, Jusko WJ, Vance JW, Cumbo TJ, Abrutyn E, DeLattre M, Gerbracht LM. Gentamicin disposition and tissue accumulation on multiple dosing. J Pharmacokinet Biopharm. 1977; 5(6).
Resman BH, Blumenthal P, Jusko WJ. Breast milk distribution of theobromine from chocolate. J Pediatr. 1977; 91(3).
Schentag JJ, Jusko WJ, Plaut ME, Cumbo TJ, Vance JW, Abrutyn E. Tissue persistence of gentamicin in man.. JAMA. 1977; 238(4).
Yaffe SJ, Gerbracht LM, Mosovich LL, Mattar ME, Danish M, Jusko WJ. Pharmacokinetics of methicillin in patients with cystic fibrosis. J Infect Dis. 1977; 135(5).
Jusko WJ, Koup JR, Vance JW, Schentag JJ, Kuritzky P. Intravenous theophylline therapy: nomogram guidelines. Ann Intern Med. 1977; 86(4).
Gorodischer R, Jusko WJ, Yaffe SJ. Renal clearance of digoxin in young infants. Res Commun Chem Pathol Pharmacol. 1977; 16(2).
Jusko WJ, Poliszczuk A. High-pressure liquid chromatographic and spectrophotometric assays for theophylline in biological fluids. Am J Hosp Pharm. 1976; 33(11).
Jusko WJ, Koup JR, AlvÃ¡n G. Nonlinear assessment of phenytoin bioavailability. J Pharmacokinet Biopharm. 1976; 4(4).
Parsons RL, Jusko WJ, Young JM. Pharmacokinetics of antibiotic absorption in coeliac disease. J Antimicrob Chemother. 1976; 2(2).
Jusko WJ. Drug dosage adjustments in diseased patients. Ration Drug Ther. 1976; 10(6).
Hunt SN, Jusko WJ, Yurchak AM. Effect of smoking on theophylline disposition. Clin Pharmacol Ther. 1976; 19(5 Pt).
Jusko WJ, Baliah T, Kim KH, Gerbracht LM, Yaffe SJ. Pharmacokinetics of gentamicin during peritoneal dialysis in children. Kidney Int. 1976; 9(5).
Gorodischer R, Jusko WJ, Yaffe SJ. Tissue and erythrocyte distribution of digoxin in infants. Clin Pharmacol Ther. 1976; 19(3).
Jusko WJ, Gretch M. Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab Rev. 1976; 5(1).
Koup JR, Jusko WJ, Goldfarb AL. pH-dependent secretion of procainamide into saliva.. J Pharm Sci. 1975; 64(12).
Koup JR, Greenblatt DJ, Jusko WJ, Smith TW, Koch-Weser J. Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses.. J Pharmacokinet Biopharm. 1975; 3(3).
Jusko WJ. Proceedings: Prediction of steady-state plasma concentrations of digoxin. Acta Pharm Suec. 1974; 11(6).
Jusko WJ, Szefler SJ, Goldfarb AL. Pharmacokinetic design of digoxin dosage regimens in relation to renal function.. J Clin Pharmacol. 1974; 14(10).
Jusko WJ, Rennick BR, Levy G. Renal exretion of riboflavin in the dog.. Am J Physiol. 1970; 218(4).
Plaut ME, Schentag JJ, Jusko WJ. Aminoglycoside nephrotoxicity: comparative assessment in critically ill patients.. J Med. ; 10(4).
Schentag JJ, Sutfin TA, Plaut ME, Jusko WJ. Early detection of aminoglycoside nephrotoxicity with urinary beta-2-microglobulin.. J Med. ; 9(3).

See all (277 more)

Books and Book Chapters:

Jusko WJ. Foundations of Pharmacodynamic Systems Analysis (Chapter 8). Systems Pharmacology and Pharmacodynamics, AAPS Advances in the Pharmaceutical Sciences Series 23. 2016.
Cao Y Jusko WJ. Mechanistic Physiologically Based Pharmacokinetic Models in Development of Therapeutic Monoclonal Antibodies (Chapter 12). ADME and Translational PK/PD of Therapeutic Proteins. 2015; Chpt(12).
Sukumaran S; Dubois DC; Jusko WJ; Almon RR. Glucocorticoid Effects on Adiponectin Expression in Adiponectin (Chapter 7). Adiponectin, Vitamins & Hormones Series. 2012; 90.
Mager DE; Jusko WJ. Mechanistic Pharmacokinetic/Pharmacodynamic Models II (Chapter 23). Pharmacometrics, The Science of Quantative Pharmacology. 2007.

Abstracts:

Morse ED; Janicke DM; Cafarell RF; Walshe JJ; Venuto RC; Apicella MA; Jusko WJ. Pharmacokinetics of intraperitoneal moxalactam in CAPD. Drug Intelligence & Clinical Pharmacy. 1984; 18.

Evaluative Studies and Case Reports:

Samtani MN, Jusko WJ. Quantification of dexamethasone and corticosterone in rat biofluids and fetal tissue using highly sensitive analytical methods: assay validation and application to a pharmacokinetic study. Biomed Chromatogr. 2007; 21(6).
Lee SJ, Jusko WJ, Salaita CG, Calis KA, Jann MW, Spratlin VE, Goldstein JA, Hon YY. Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition. J Clin Pharmacol. 2006; 46(5).
Lima JJ, Kuritzky PM, Schentag JJ, Jusko WJ. Fetal uptake and neonatal disposition of procainamide and its acetylated metabolite: a case report. Pediatrics. 1978; 61(3).
Rose JQ, Choi HK, Schentag JJ, Kinkel WR, Jusko WJ. Intoxication caused by interaction of chloramphenicol and phenytoin.. JAMA. 1977; 237(24).
Yurchak AM, Jusko WJ. Theophylline secretion into breast milk. Pediatrics. 1976; 57(4).

Professional Memberships:

Phi Lambda Sigma Pharmacy Leadership Society (2002–present)
European Federation for Pharmaceutical Sciences (1999–2000)
American College of Clinical Pharmacology (1989–present)
American Association of Pharmaceutical Scientists (1986–present)
American College of Clinical Pharmacy (1980–present)
Federation Internationale Pharmaceutique (1980–present)
American Society for Clinical Pharmacology and Therapeutics (1976–present)
American Society for Microbiology (1975–1994)
American Society for Pharmacology and Experimental Therapeutics (1974–present)
American Association of Colleges of Pharmacy (1972)
American Association for the Advancement of Science (1970–present)
Academy of Pharmaceutical Research and Science (1969–present)
Rho Chi Pharmaceutical Honor Society (1968)
Kappa Psi Pharmaceutical Fraternity (1962–1965)
American Pharmaceutical Association (1962–present)

See all (5 more)

Presentations:

"3-day Buffalo Post-Graduate Course on Pharmacokinetics and Pharmacodynamics" Annual 3-day Buffalo Post-Graduate Course on Pharmacokinetics and Pharmacodynamics, SUNY AT BUFFALO, PHC DEPARTMENT (2018)
"3-day Buffalo Post-Graduate Course on Pharmacokinetics and Pharmacodynamics" Annual 3-day Buffalo Post-Graduate Course on Pharmacokinetics and Pharmacodynamics, SUNY AT BUFFALO, PHC DEPARTMENT (2017)
"3-day Buffalo Post-Graduate Course on Pharmacokinetics and Pharmacodynamics" 3-day Buffalo Post-Graduate Course on Pharmacokinetics and Pharmacodynamics (2016)
"Multiscale PD Studies of Drug Combination Between Gemcitabine & Trabectedin for the Treatment of Pancreatic Cancer. Scale III. Dynamic Proteomic Responses of Pancreatic Cancer Cells Druing Combination Exposures to Gemcitabine & Trabectedin" Roche ‘Increasing Drug Development Success Through Quantitative Systems Pharmacology’, NY Academy of Sciences Symposium (2015)
"Multiscale Pharmacodynamic (PD) Studies of Drug Combination Between Gemcitabine & Trabectedin for the Treatment of Pancreatic Cancer. Scale II. Mathematical Models of Cell Cycle Distribution of Gemcitabine, Trabectidin & Combinations on Pancreatic Cancer" Roche ‘Increasing Drug Development Success Through Quantitative Systems Pharmacology’, New York Academy of Sciences Symposium (2015)
"Network Analysis of Proteomics of Gemcitabine and Birinapant Combinations in Apoptosis Signaling of Pancreatic Cancer Cells" Roche ‘Increasing Drug Development Success Through Quantitative Systems Pharmacology’, New York Academy of Sciences Symposium (2015)
"Dynamic Proteomic Responses of Pancreatic Cancer Cells During Combination Exposures to Gemcitabine and Ecteinascidin ET 743" American Association of Pharmaceutical Scientists (2015)
"Mechanistic Modeling of Tissue-Specific Receptor/Gene-Mediated Pharmacodynamic Effects of Corticosteroids and Role of Circadian Rhythms on GILZ mRNA Expression" American Association of Pharmaceutical Scientists (2015)
"Minimal Physiologically-Based Pharmacokinetic (mPBPK) Model for a Monoclonal Antibody (mAb) against Interleukin-6 in Mice with Collagen-Induced Arthritis (CIA)”" American Conference on Pharmacometrics (2015)
"Multiscale Pharmacodynamic Studies of Gemcitabine and Trabectedin Combinations for Treatment of Pancreatic Cancer" Department of Pharmaceutical Sciences, 323266818 (2015)
"Network Analysis of Proteomics of Gemcitabine and Birinapant Combinations in Pancreatic Cancer Cells" American Association of Pharmaceutical Scientists (2015)
"Pharmacodynamics of Suppression of Free TNF-a by Infliximab in Plasma of Rats" American Association of Pharmaceutical Scientists (2015)
"What We Do in Pharmaceutical Sciences" University of Buffalo - PharmD IPPE program, 323266818 (2015)
"Moving From Basic PK/PD Towards Systems Pharmacology: Whither Pediatrics?" T32 Programs in Pediatric Clinical Pharmacology, National Institute of Child Health and Human Development (2015)
"Moving From Basic Towards Systems Pharmacodynamic Models" Faculte de Pharmacie de Paris, Universite Paris Descartes (2015)
"Inclusion of Tissue Target Dynamics in Minimal PBPK Models for mAb PK/PD" Seventh Annual Symposium, Center for Protein Therapeutics, 323266818 (2015)
"Suppression of Free TNF-a With Infliximab in Plasma and Joints in CIA Rats" Seventh Annual Symposium, Center for Protein Therapeutics, 323266818 (2015)
"3-day course on Pharmacokinetic-Pharmacodynamic Modeling" Merck Pharmaceuticals (2015)
"Transitioning From Basic PK/PD To Systems Pharmacology" NJ/PA Branch of the International Society for Pharmacometrics (2015)
"Effects of Altered FcgR Expression by Dexamethasone on Monoclonal Antibody Pharmacokinetics in Rats with Rheumatoid Arthritis" 7th Annual Postdoc Research Symposium, 323266818 (2015)
"Annual 3-day Buffalo Post-Graduate Course on Pharmacokinetics and Pharmacodynamics" Annual 3-day Buffalo Post-Graduate Course on Pharmacokinetics and Pharmacodynamics (2015)
"PBPK Modeling of Etanercept Biodistribution in Arthritic Rats" Department of Pharmaceutical Sciences, 323266818 (2015)
"Two-Day Buffalo Workshop on Systems Pharmacology" Two-Day Buffalo Workshop on Systems Pharmacology, 323266818 (2015)
"Network Analysis of Proteomics of Gemcitabine and Birinapant Combinations in Apoptosis Signaling of Pancreatic Cancer Cells" UB Sigma Xi Poster Day, 323266818 (2015)
"Network Modeling of Gemcitabine and Birinapant Proteomics in Pancreatic Cancer Cells" Department of Pharmaceutical Sciences, 323266818 (2015)
"Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model" AAPS Annual Meeting and Exposition (2014)
"Biodistribution of Etanercept to Tissues and Sites of Inflammation in Arthritic Rats" American Association of Pharmaceutical Scientists (2014)
"Incorporating Target-Mediated Drug Disposition in a Minimal Physiologically-Based Pharmacokinetic Model for Monoclonal Antibodies" AAPS Annual Meeting and Exposition (2014)
"Mechanism-Based Drug Interactions of Gemcitabine and Birinapant in Pancreatic Cancer Cells" AAPS Annual Meeting and Exposition (2014)
"Second-Generation Minimal Physiologically-Based Pharmacokinetic Model for Monoclonal Antibodies" American Association of Pharmaceutical Scientists (2014)
"Department Highlights” and “Moving from Basic towards Systems Pharmacodynamic Models" Thirteenth Buffalo Pharmaceutics Symposium, 323266818 (2014)
"Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model" Thirteenth Buffalo Pharmaceutics Symposium, 323266818 (2014)
"Mechanism-Based Interaction Model of Gemcitabine and Ecteinascidin (Et-743) in Pancreatic Cancer Cells" Thirteenth Buffalo Pharmaceutics Symposium, 323266818 (2014)
"Mechanism-Based Drug Interactions of Gemcitabine and Birinapant in Pancreatic Cancer Cells" Thirteenth Buffalo Pharmaceutics Symposium, 323266818 (2014)
"Second-Generation Minimal PBPK Model for mAb Pharmacokinetics" 6th Annual Symposium Center for Protein Therapeutics, 323266818 (2014)
"3-day Course on Pharmacokinetics and Pharmacodynamics" University of Gdansk (2014)
"Minimal Physiologically-Based Pharmacokinetic Modeling of Monoclonal Antibodies" Servier Inc. (2014)
"Pharmacokinetics and Pharmacodynamics & Systems Pharmacology" Annual 4-day Buffalo Course on Pharmacokinetics and Pharmacodynamics & Systems Pharmacology (2014)
"PK/PD Modeling: Lessons from Corticosteroids" Medical University of Gdansk (2014)
"Workshop on Pharmacodynamics and Systems Pharmacology at Dublin City University" Dublin City University (2014)
"PK/PD Modeling of Anti-Infective Drugs" Hoffman LaRoche (2014)
"An Extensive and Reproducible Ion-Current-Based Method Enabled Large-Scale Proteomic Assessment of Corticosteroid Treatment in 60 Animals" American Association of Pharmaceutical Scientists (2013)
"Mechanism-Based Drug Interaction Model of Gemcitabine and Ecteinascidin (Et-743) in Pancreatic Cancer Cells" American Association of Pharmaceutical Scientists (2013)
"PK/PD Modeling in Inflammation" Department of Oral Biology, 323266818 (2013)
"Population Pharmacokinetics of Oral Baclofen in Pediatric Patients with Cerebral Palsy" Annual Meeting of the Child Neurology Society (2013)
"Profiling Diabetes Disease Progression in GK Rats and Intervention with Salsalate" American Association of Pharmaceutical Scientists (2013)
"Applications of Minimal PBPK Models in mAb Pharmacokinetics" 5th Annual Symposium Center for Protein Therapeutics (2013)
"Distribution of Etanercept to Sites of Inflammation in Collagen-Induced Arthritic Rats" 5th Annual Symposium Center for Protein Therapeutics, 323266818 (2013)
"Roles of FcgR in Pharmacokinetic Interactions of Immunosuppressants with mAb in Rheumatoid Arthritis" 5th Annual Symposium Center for Protein Therapeutics, 323266818 (2013)
"Pharmacokinetic-Pharmacodynamic Modeling" Genentech, Inc. (2013)
"CELL CYCLE MODELING OFFERS A PLATFORM TO OPTIMIZE COMBINATION OF CYTARABINE AND FLT3 INHIBITORS IN ACUTE MYELOID LEUKEMIA" Congress of the European Hematology Association, 18th Congress of the European Hematology Association (2013)
"Evolution of Mechanistic PK/PD Modeling - Our Future?" ASCPT 2013 Annual Meeting, ASCPT (2013)
"PHARMACODYNAMIC MODELING OF CELL CYCLE EFFECTS OF CYTARABINE AND FLT3 INHIBITORS ON ACUTE MYELOID LEUKEMIA CELLS" ASCPT 2013 Annual Meeting, ASCPT (2013)
"Applications of Minimal Physiologically-Based Pharmacokinetic Models" Research Institute of Pharmaceutical Sciences, Seoul National University (SNU) (2012)
"Moving PK/PD from Basic Towards Systems Pharmacology" 2012 International Conference of the Korean Society of Pharmaceutical Sciences and Technology (KSPST), KSPST (2012)
"Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics: Lessons From Corticosteroids" The Catholic University of Korea School of Medicine, Korean Society of Clinical Pharmacology and Therapeutics (2012)
"Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics: Lessons From Corticosteroids" Biomedical Research Institute, Chonnam National University Hospital (CNHU) (2012)
"Application of Minimal Physiologically-based Pharmacokinetic Models" 2012 AAPS Annual Meeting and Exposition, AAPS (2012)
"Mechanism-based Population Pharmacokinetic and Pharmacodynamic Modeling of Intravenous and Intranasal Dexmedetomidine" 2012 AAPS Annual Meeting and Exposition, AAPS (2012)
"Modeling Effects of Dexamethasone on Disease Progression of Bone Mineral Density in Collagen-induced Arthritic Rats" 2012 AAPS Annual Meeting and Exposition, AAPS (2012)
"Population Pharmacokinetics Analysis of Orally Administrated Baclofen in Pediatric Patients with Cerebral Palsy" 2012 AAPS Annual Meeting and Exposition, AAPS (2012)
"Proteome-level Pharmacokinetic/Pharmacodynamic Analysis of Corticosteroid-responsive Proteins in Rat Liver" 2012 AAPS Annual Meeting and Exposition, AAPS (2012)
"Extensive, proteome-level investigation of the corticosteroid pharmacodynamics with 12 time points using a reproducible and comprehensive ion-current-based profiling strategy" HUPO 2012 11th Annual World Congress, HUPO (2012)
"Moving PK/PD from Basic towards Systems Pharmacology" 2012 American College of Clinical Pharmacology (ACCP) Annual Meeting, American College of Clinical Pharmacology (2012)
"Pharmacokinetics/Pharmacodynamics/Pharmacogenomics: Lessons from Corticosteroids" 2012 American College of Clinical Pharmacology (ACCP) Annual Meeting, American College of Clinical Pharmacology (2012)
"Prednisone Dose and Exposure in Chronic Renal Transplant Recipients: One Size Does NOT Fit All" American Transplant Congress, American Transplant Congress (2012)
"Take it With Breakfast: But Does Food Reduce Prednisone Exposure As Much As It Reduces CNI Exposure in Renal Transplant Patients?" American Transplant Congress, American Transplant Congress (2012)
"Effects of sonic hedgehog inhibitor combined with nanoparticulate drug delivery on vascular permeability and efficacy in a pancreatic cancer model." Annual Meeting of the American Association for Cancer Research, American Association for Cancer Research (2012)
"Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine" 4th Annual UB Postdoc Research Symposium, University at Buffalo (2012)
"Multi-scale assessment of Everolimus and Sorafenib Combination in Pancreatic Cancer" American Association for Cancer Research, AACR (2012)
"Pharmacokinetic/Pharmacodynamic Modeling of GLP-1 in Healthy Rats" 4th Annual UB Postdoc Research Symposium, University at Buffalo (2012)
"Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone Effects on iNOS mRNA Expression and Nitric Oxide During LPS-Induced Inflammation in Rats" 4th Annual UB Postdoc Research Symposium, University at Buffalo (2012)
"PK/PD/Disease Modeling in Cancer Chemotherapy" Hoffman La Roche, Hoffman La Roche (2012)
"What We Do in Pharmaceutical Sciences" UB Biology Honors Program (2012)
"Moving PK/PD From Basic Towards Systems Pharmacology" Rosa & Co. Impact of Modeling & Simulation in Drug Development Webinar, Rosa & Co. LLC. (2011)
"Population PK and PD Analysis of Oral Baclofen in Pediatric Patients with Cerebral Palsy" Pediatric Neurology Cerebral Palsy Center, Pediatric Neurology Cerebral Palsy Center (2011)
"Mechanistic Modeling of Tissue-specific Effects of Corticosteroids and Circadian Rhythms on Phosphoenolpyruvate Carboxykinase Expression in Rat Liver and Adipose Tissue" 2011 AAPS Annual Meeting and Exposition, AAPS (2011)
"Modeling Diabetes Disease Progression and Salsalate Intervention in Goto-Kakizaski Rats" 2011 AAPS Annual Meeting and Exposition, AAPS (2011)
"Modeling Pharmacokinetics/Pharmacodynamics of Abatacept and Disease Progression in Collagen-induced Arthritic Rats - A Population Approach" 2011 AAPS Annual Meeting and Exposition, AAPS (2011)
"Population Pharmacokinetic-Pharmacodynamic-Disease Progression Model for Effects of Anakinra in Lewis Rats with Collagen-induced Arthritis" 2011 AAPS Annual Meeting and Exposition, AAPS (2011)
"Population Physiologically-based Pharmacokinetic Models for Everolimus and Sorafenib in Pancreatic Cancer Xenograft Mice" 2011 AAPS Annual Meeting and Exposition, AAPS (2011)
"Systems Pharmacological Analysis of Molecularly Targeted Agents in Pancreatic Cancer: Pharmacodynamic Design of Novel Therapeutic Trials" Clinical and Translational Research Colloquium, University at Buffalo (2011)
"The Relevance of Chronobiology in PK/PD" 2011 AAPS Annual Meeting and Exposition, AAPS (2011)
"Pharmacokinetic/Pharmacodynamic/Disease Progression Model of Anakinra, an Interleukin-1 Receptor Antagonist, in Collagen-Induced Arthritic Rats" Third Annual Symposium Center for Protein Therapeutics, University at Buffalo (2011)
"Pharmacokinetic/Pharmacodynamic/Disease Progression Model of Effects of Abatacept in Collagen-Induced Arthritic Rats" Third Annual Symposium Center for Protein Therapeutics, University at Buffalo (2011)
"Assessment of L-Cell Function Based on GLP-1 Response in an Oral Glucose Tolerance Test" 2011 PAGE Meeting, PAGE (2011)
"Modeling type 2 diabetes progression in newly diagnosed patients" Post-Doctoral Fellowship Day, University at Buffalo (2011)
"PK/PD Modeling of Drug Effects in Inflammation" Bristol Myers Squibb, Bristol Myers Squibb (2011)
"Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis" Post-Doctoral Fellowship Day, University at Buffalo (2011)
"Genome-wide analysis of circadian oscillations in gene expression in lung and its implications in lung homeostasis, repair and diseases" EXPERIMENTAL BIOLOGY 2011, APS (2011)
"Modeling Diabetes Progression in Goto-Kakizaki Rat and Salsalate Intervention" Pharmaceutical Sciences Poster Day, University at Buffalo (2011)
"Physiologically-Based Pharmacokinetics and Interactions of Everolimus and Sorafenib in Mice" American Association for Cancer Research, AACR (2011)
"Mechanism-Based PK/PD Model of Pramlintide in Patients with Type 1 Diabetes" AAPS Annual Meeting and Exposition, AAPS (2010)
"Modeling chemotherapeutic interactions of sorafenib and everolimus effects on pancreatic cancer cells" AAPS Annual Meeting and Exposition, AAPS (2010)
"Pharmacodynamic Interaction of Everolimus and Sorafenib Using In Vitro Whole Blood Lymphocyte Proliferation" AAPS Annual Meeting and Exposition, AAPS (2010)
"Pharmacokinetic - Pharmacodynamic - Disease Progression Model for Effect of Etanercept in Lewis Rats with Collagen-Induced Arthritis" AAPS Annual Meeting and Exposition, AAPS (2010)
"Pharmacokinetic-Pharmacodynamic-Disease Progression Model for Effect of Etanercept in Lewis Rats with Collagen-Induced Arthritis" AAPS Annual Meeting and Exposition, AAPS (2010)
"Pharmacokinetics and Pharmacodynamics of Rosiglitazone in Type 2 Diabetic Goto-Gakizaki (GK) Rats" AAPS Annual Meeting and Exposition, AAPS (2010)
"The Development of Mechanistic Population Pharmacokinetic Models to Support the Development of Targeted Release Characteristics from Modified Release Dosage Forms" AAPS Annual Meeting and Exposition, AAPS (2010)
"Department Highlights & Introduction and Historical Perspectives of PK/PD" 12th Buffalo Pharmaceutics Symposium, University at Buffalo (2010)
"Pharmacokinetic/Pharmacodynamic modeling of GLP-1 in healthy rats" 12th Buffalo Pharmaceutics Symposium, University at Buffalo (2010)
"PK/PD Modeling of Etanercept" Meeting of the Center for Protein Therapeutics (2010)
"Pediatric Pharmacokinetics: Lithium, Baclofen, and Hydroxyurea" 2010 Best Pharmaceuticals for Children Act Annual Meeting, National Institute of Child Health and Human Development & National Institutes of Health (2010)
"Pharmacokinetic - Pharmacodynamic - Disease Progression Model for Effect of Etanercept in Lewis Rats with Collagen-Induced Arthritis" Annual Pharmaceutics Graduate Student Research Meeting (2010)
"Pharmacokinetics and Pharmacodynamics of Anti-CD3 Monoclonal Antibody, Otelixizumab in Subjects with Diabetes and Psoriasis" The Annual Meeting of the Population Approach Group in Europe, Population Approach Group in Europe (2010)
"Pharmacodynamic Interaction of Everolimus and Sorafenib Using In Vitro Whole Blood Lymphocyte Proliferation" Pharmacology Day 2010, University at Buffalo (2010)
"Target-Mediated Pharmacokinetic Modeling of Exendin-4 Disposition in Rats, Monkeys and Humans" Pharmacology Day 2010, University at Buffalo (2010)
"Various" Annual Course in PK/PD Modeling, University at Buffalo (2010)
"Research Perspectives of the UB Department of Pharmaceutical Sciences" SUNY Upstate Cancer Research Institute Workshop, SUNY Upstate Cancer Research Institute (2010)
"Systems Pharmacology of Anti-Inflammatory Effects of Corticosteroids" Mount Sinai School of Medicine Workshop, Mount Sinai School of Medicine (2010)
"PK/PD Modeling of Anti-Inflammatory Drug Effects" Drug Metabolism Department at Hoffman La Roche, Hoffman La Roche (2010)
"Assessing Drug Accumulation and Half-Lives During Multiple-Dosing Conditions" Annual Meeting of AAPS, AAPS (2009)
"Comparison of Liver and Muscle Genes for Presence of Circadian Rhythms" Annual Meeting of AAPS, AAPS (2009)
"Population Pharmacokinetic-Pharmacodynamic Model for the Triglyceride Lowering Effect of a PPAR Agonist: A Phase I Study" Annual Meeting of AAPS, AAPS (2009)
"Role of Sex (Gender) in Drug Kinetics and Dynamics" Frontier Science and Technology Research Foundation, Frontier Science and Technology Research Foundation (2009)
"Target-Mediated Pharmacokinetic Modeling of Exendin-4 Disposition in Rats, Monkeys and Humans" Annual Meeting of AAPS, AAPS (2009)
"Pharmacokinetic/Pharmacodynamic Modeling of Glucose Clamp Effects of Inhaled Insulin" American Conference on Pharmacometrics, ACoP (2009)
"Population PK/PD Modeling of the Effects of Vildagliptin on Active GLP-1, Glucose, and Insulin" American Conference on Pharmacometrics, ACoP (2009)
"Disease Progression Model in Type 2 Diabetic Rats" Pharmacology Day 2009 (2009)
"Disease Progression Model in Type 2 Diabetic Rats" Pharmacology Day 2009 (2009)
"Gene Expression as a Pharmacodynamic Marker" AAPS Workshop on Translational Biomarkers (2009)
"Mechanism-Based PK/PD Model of Pramlintide in Type 1 Diabetic Patients" Pharmacology Day 2009 (2009)
"Methods of Utilizing Baseline Values for Indirect Response Models" Pharmacology Day 2009 (2009)
"Model-Based Comparison of Binocrit and Erypo Pharmacokinetics after Repeated I.V. and S.C. Administration" WCN (World Congress of Nephrology) (2009)
"Role of Sex/Gender in Drug Kinetics and Dynamics" City-Wide Grand Rounds, Erie County Medical Center (2009)
"Systems pharmacology of anti-inflammatory effects of corticosteroids" Experimental Biology 2009 Meeting (2009)
"Animal Scaling of Pharmacokinetics and Pharmacodynamics" , Hoffman-LaRoche (2009)
"Pharmacokinetic and Pharmacodynamic Modeling of Anti-inflammatory Drugs" , Hoffman-LaRoche (2009)
"Disease Progression Model in Type 2 Diabetic Goto-Kakizaki Rats" American Association of Pharmaceutical Sciences Meeting (2008)
"Mechanism-Based Modeling of Leptin Production and Effect on Food Intake in Normal Wistar (CON) and Type 2 Diabetic Goto-Kakizki Rats (GK) on Different Diets" American Association of Pharmaceutical Sciences Meeting (2008)
"Mechanism-Based Pharmacokinetic Pharmacodynamic (PKPD) Model for the Inverse Inoculum Effect of Imipenem Against Psedomonas Aeruginosa" American Association of Pharmaceutical Sciences Meeting (2008)
"Modeling Sitagliptin Effects on Glucagon-Like Peptide 1 (GLP-1) and Glucose in Type 2 Diabetic Patients (T2DM)" American Association of Pharmaceutical Sciences Meeting (2008)
"Bioequivalence of Biosimilars - Is Pharmacodynamic Equivalence Sufficient?" Ehrlich II -2nd World Conference on Magic Bullets Celebrating the 100th Anniversary of the Nobel Prize Award to Paul Ehrlich (2008)
"Corticosteroids - Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, and Disease Progression" Ehrlich II -2nd World Conference on Magic Bullets Celebrating the 100th Anniversary of the Nobel Prize Award to Paul Ehrlich (2008)
"First-Dose Pharmacokinetics of Lithium Carbonate in Children and Adolescents" Annual Meeting of the American Academy of Child and Adolescent Psychiatry, AACAP (2008)
"Pharmacokinetic Pharmacodynamic Concepts" Ehrlich II -2nd World Conference on Magic Bullets Celebrating the 100th Anniversary of the Nobel Prize Award to Paul Ehrlich (2008)
"Exposure-Response Modeling" Land O'Lakes Conference on Drug Metabolism/Applied Pharmacokinetics, University of Wisconsin (2008)
"Multiple-Pool Lifespan Models for Neutropenia to Assess the Population Pharmacodynamics of Unbound Paclitaxel from Two Formulations in Cancer Patients" Quantitative and Systems Pharmacology Workshop, National Institute of General Medical Sciences (2008)
"Population PK/PD Modeling of Inhibition of Dipeptidyl Peptidase IV" Quantitative and Systems Pharmacology Workshop, National Institute of General Medical Sciences (2008)
"Systems PK/PD/PG/DIS model for anti-inflammatory effects of corticosteroids" Quantitative and Systems Pharmacology Workshop, National Institute of General Medical Sciences (2008)
"Utility of PK/PD modeling in drug development & PK/PD modeling of anti-inflammatory drugs." Merial Pharmaceuticals, Merial Pharmaceuticals (2008)
"Erythropoietin Receptor-Mediated Disposition and Dynamic Model for Human Recombinant Erythropoietin (rHuEPO)" AAPS Annual Meeting (2007)
"Characterization and application of a new model for the assessment of non-competitive drug-drug interactions" AAPS Annual Meeting (2006)
"Development of mathematical model for chemotherapy-induced anemia in rats and its application to selection of rHuEPO dosing strategy" AAPS Annual Meeting (2006)
"Population pharmacokinetic and pharmacodynamic modeling of a novel erythropoietin receptor agonist, HematideTM, in healthy volunteers" , AAPS Annual Meeting (2006)

See all (135 more)

Service Activities:

University of Buffalo, Search Committee for Dean, School of Pharmacy; Committee Member (2013)
E Fund Proposal Review Committee; Committee Member (2012)
Advisory Committee, Center for Clinical and Translational Research Grant Application; Committee Member (2012–2015)
Pilot Studies Oversight Review Committee; Committee Member (2012)
Committee; AAPS/AACP NIH Research Task Force; Committee Member (2011)
VPR External Advisory Committee; Medical College of Wisconsin; Committee Member (2011–2014)
External Reviewer, Promotion; Rutgers University, New Jersey; External Reviewer (2011)
External Reviewer, Promotion; Eschelman School of Pharmacy, University of North Carolina; External Reviewer (2011)
NIDDK - National Institute of Diabetes and Kidney Diseases Special Emphasis Panel; NIDDK - Grant Applicatins; Panel Member (2011)
Program Project: Mechanisms of Drug Disposition During Pregnancy; NIH - Program Project Grant Applications: Mechanisms of Drug Disposition During Pregnancy; Panel Member (2011)
RFA Panel: Developmental Pharmacology; NIH - RFA Panel: Developmental Pharmacology; Panel Member (2011)
Special Review Committee for Glue Grants; NIH Served as chair for NIH Special Review Committee for Glue Grants, March 25, 2011; Reviewer (2011)
School of Pharmacy and Pharmaceutical Sciences Accreditation Review Committee - Organization and Management; Committee Member (2010)
Reviewer; NIH Director‘s Opportunity 5 Themes General Basic Science; Reviewer (2010)
NIH Committee Meeting - Bethesda, MD; Quantitative and Systems Pharmacology; Committee Member (2010)
Special Emphasis Panel; NIGMS; Panel Member (2009)
Reviewer; National Institute of Diabetes and Digestive and Kidney Diseases; Reviewer (2009)
International Scientifica Advisory Board; 6th International Symposium on Measurement and Kinetics of In Vivo Drug Effects, The Netherlands; Advisory Board (2009)
Planning Committee; Translational Biomarkers for Accelerating Drug Development: From Preclinical to Clinical; Committee Member (2009)
Special Emphasis Panel; NIGMS; Panel Member (2009)
SUNY Distinguished Service Review Committee; Committee Member (2008)
Organizing Committee; AAPS Workshop on Biomarkers and Drug Development; Committee Member (2008)
MRBS Faculty Committee; Committee Member (2007)
Organizing Committee; Workshop on Pharmacology and Systems Biology; Committee Member (2007)
Selection Committee; Volwiler Award, Am Assn Coll Pharmacy; Committee Member (2006–2008)
School of Pharmacy Awards Committee; Committee Member (2005)
Executive Committee; Committee Member (2001–2016)
School Promotions and Tenure Committee; Committee Member (2001–2016)

School News:

In the Media:

Clinical Specialties:

Clinical Offices:

Insurance Accepted:

Contact Information

404 Pharmacy Building
Buffalo, NY 14214-8033
Phone: (716) 645-2855
Fax: 7168296569
wjjusko@buffalo.edu

View map

View faculty website

William J. Jusko PhD

William J. Jusko
PhD

Specialty/Research Focus

Professional Summary:

Education and Training:

Employment:

Awards and Honors:

Research Expertise:

Grants and Sponsored Research:

Patents:

Journal Articles:

Books and Book Chapters:

Abstracts:

Evaluative Studies and Case Reports:

Professional Memberships:

Presentations:

Service Activities:

School News:

In the Media:

Clinical Specialties:

Clinical Offices:

Insurance Accepted:

Contact Information

Academics

Admissions

Departments and Offices

Research Centers

Contact Us

Find People

Visit and Explore

ACPE Accredited

School of Pharmacy and Pharmaceutical Sciences